GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Change In Receivables

MBCOF (Marvel Biosciences) Change In Receivables : $0.00 Mil (TTM As of Oct. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences Change In Receivables?

Marvel Biosciences's change in receivables for the quarter that ended in Oct. 2024 was $-0.01 Mil. It means Marvel Biosciences's Accounts Receivable increased by $0.01 Mil from Jul. 2024 to Oct. 2024 .

Marvel Biosciences's change in receivables for the fiscal year that ended in Jul. 2024 was $0.00 Mil. It means Marvel Biosciences's Accounts Receivable declined by $0.00 Mil from Jul. 2023 to Jul. 2024 .

Marvel Biosciences's Accounts Receivable for the quarter that ended in Oct. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Marvel Biosciences's liquidation value for the three months ended in Oct. 2024 was $-2.35 Mil.

Marvel Biosciences Change In Receivables Historical Data

The historical data trend for Marvel Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Change In Receivables Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
Change In Receivables
-0.03 -0.02 - -0.02 -

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 0.02 -0.01

Marvel Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences  (OTCPK:MBCOF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Marvel Biosciences's Days Sales Outstanding for the quarter that ended in Oct. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Marvel Biosciences's accounts receivable are only considered to be worth 75% of book value:

Marvel Biosciences's liquidation value for the quarter that ended in Oct. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.06-2.407+0.75 * 0+0.5 * 0
=-2.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Change In Receivables
Comparable Companies
XCNQ:ASEP XCNQ:LOBE TSXV:QPT TSX:APLI XCNQ:RIZE TSXV:XRTX TSXV:IOT TSXV:IBO TSXV:CYTO XCNQ:NURL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
MRVL:Canada
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Website
https://www.marvelbiotechnology.com
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.